Details of the Drug Formulations

General Information of Drug (ID: DMWU0I2)

• Drug Name: Pralsetinib Drug Info
• Synonyms: GBLBJPZSROAGMF-SIYOEGHHSA-N; Blu667; 2097132-94-8; SCHEMBL18806610; SCHEMBL18789229; SCHEMBL18789228; GTPL10033; BLU-668; EX-A1944; HY-112301; CS-0044766; N-[(1S)-1-[6-(4-fluoropyrazol-1-yl)pyridin-3-yl]ethyl]-1-methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]cyclohexane-1-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25.Y	Approved	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

• Cross-matching ID:
  PubChem CID: 129073603
  CAS Number: 2097132-94-8
  TTD ID: D0OD2I
  ACDINA ID: D01355

Full List of Drug Formulations Containing This Drug

Pralsetinib 100 mg capsule

Company	Formulation ID	FDA Description
Blueprint Medicines Corporation	F23262	Citric Acid; Hydroxypropyl Methylcellulose (Hpmc); Magnesium Stearate; Microcrystalline Cellulose (Mcc); Pregelatinized Starch; Sodium Bicarbonate; Fd&C Blue 1 (Brilliant Blue Fcf); Hypromellose; Titanium Dioxide; Butyl Alcohol; Dehydrated Alcohol; Isopropyl Alcohol; Potassium Hydroxide; Propylene Glycol; Purified Water; Shellac; Strong Ammonia Solution; Titanium Dioxide

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)